ResMed Inc. logo

ResMed Inc. (RMD)

Market Closed
1 Sep, 20:00
NYSE NYSE
$
231. 36
-8.74
-3.6402%
$
34.19B Market Cap
27.49 P/E Ratio
2.1% Div Yield
976,727 Volume
6.52 Eps
$ 240.1
Previous Close
Add Transaction
Day Range
230.18 242.4
Year Range
180.27 284.87
Want to track RMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 2 years ago
RMD ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ResMed Inc. investment

RMD ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ResMed Inc. investment

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
ResMed Shares Breathing Life into Big Money Portfolios

ResMed Shares Breathing Life into Big Money Portfolios

Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.

Fxempire | 2 years ago
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.

RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.

NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?

ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 2 years ago
ATTENTION RMD SHAREHOLDERS: Investors who lost money on ResMed Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

ATTENTION RMD SHAREHOLDERS: Investors who lost money on ResMed Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.

RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
ResMed Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - RMD

ResMed Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - RMD

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
An Investigation Has Commenced on Behalf of ResMed Inc. Shareholders. Contact Levi & Korsinsky to Discuss your RMD Losses

An Investigation Has Commenced on Behalf of ResMed Inc. Shareholders. Contact Levi & Korsinsky to Discuss your RMD Losses

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities

ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities

ResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.

Benzinga | 2 years ago
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand

ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand

ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.

Zacks | 2 years ago
Lost Money on ResMed Inc. (RMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Lost Money on ResMed Inc. (RMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Accesswire | 2 years ago
Loading...
Load More